Nasdaq grants Vivos extension to March 19, 2024 for equity compliance; delisting risk persists

Vivos Therapeutics, Inc.

Regained minimum bid price compliance on Nov 9, 2023 after 1-for-25 reverse stock split.
Nasdaq Panel granted extension until March 19, 2024 to meet $2.5M minimum stockholders' equity requirement.
Company raised ~$4M in private placement but warns additional capital may be needed; failure risks delisting.
Must provide compliance update by Jan 31, 2024; non-compliance could restart delisting proceedings.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.